Expression of the cell cycle inhibitor p27(KIP1) is a new prognostic marker associated with survival in epithelial ovarian tumors

American Journal of Pathology

Volumn 154, Issue 1, 1999, Pages 119-125

  Newcomb, Elizabeth W ^a   Sosnow, Meg ^a   Demopoulos, Rita I ^a   Zeleniuch Jacquotte, Anne ^a   Sorich, Joan ^a   Speyer, James L ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; EPITHELIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0032943896     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65258-3     Document Type: Article

References (40)

1. Lundis SH, Murray T, Bolden S, Wingo PA: Cancer statistics CA. Cancer J Clin 1998, 48:6-13
2. Thigpen JT, Vance RB, Khansur T: Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993, 71:1559-1564
3. Dive C, Hickman, JA: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991, 65: 192-196
4. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young, LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995, 11:1217-1228
5. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56:556-562
6. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991, 51:2979-2984
7. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993, 85:1513-1519
8. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75:1327-1338
9. Klemi PJ, Pylkkanen L, Kiiholma P, Kurvinen K, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995, 76:1201-1208
10. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta G, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997, 3:231-234
11. Kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997, 3:227-230
12. Tan P, Cady B, Wanner M, Worland P, Cukor B, Fiorentino M, Magi-Galluzzi C, Lavin P, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 1997, 57:1259-1263
13. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997, 3:222-225
14. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small lung cancer. Cancer Res 1997, 57:3381-3385
15. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 1997, 3:593
16. 1 prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998, 58:542-548
17. Yang RM, Naitoh, J, Murphy MJ, Wang H-J, Philipson J, DeKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159: 941-945
18. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998, 58:1730-1735
19. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74
20. Pagano M, Tam SW, Theodoras AM, Beer-Romano P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of ubiquitin-proteosome pathway in regulating the abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685
21. Piccart MJ, Speyer JL, Wernz JC, Noumoff J, Beller U, Beckman M, Dubin N, Demopoulos R, Muggia F: Advanced ovarian cancer: three-year results of a (6-8 month), 2 drug cisplatin-containing regimen. Eur J Cancer Clin Oncol 1987, 23:631-641
22. Beller U, Speyer JL: Current issues in the evaluation and treatment of epithelial carcinoma of the ovary. In: Experimental and Clinical Progress in Cancer Chemotherapy. Edited by Bottino JC, Opfell RW, Muggia FM. Boston, Martinus Nijhoff, 1985, pp 235-263
23. Speyer JL, Mandeli J, Hochster H, Runowicz C, Wadler S, Wallach R, Cohen C, Oette D, Sorich J, Demakos E, Gelpke L, Goldberg G, Bruckner HJ, Holland J: A Phase I trial of cyclophosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer. Gynecol Oncol 1995, 56:387-394
24. KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998, 58:114-122
25. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997, 94:6380-6385
26. Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997, 88:625-629
27. kip1 expression in endocrine and other tumors. Am J Pathol 1997, 150:401-407
28. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale A-L, Trope C, Holm R: TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997, 181:158-165
29. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE: An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996, 13: 117-123
30. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G: p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993, 24:1175-1179
31. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K: p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994, 53:301-306
32. Rohlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Loning T: p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 1997, 123:496-501
33. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Karzmann JA, Roche PC: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994, 12:64-69
34. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997, 80:892-898
35. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver N, Steren A: National survey of ovarian carcinoma. VI. Critical assessment of current international federations of gynecology and obstetrics staging system. Cancer 1993, 72:3007-3011
36. Brescia RJ, Barakat RA, Beller U, Frederickson G, Suhrland MJ, Dubin N, Demopoulos RI: The prognostic significance of nuclear DNA content in malignant epithelial tumours of the ovary. Cancer 1990, 65:141-147
37. Diebold J, Suchy B, Baretton GB, Blasenbreu S, Meier W, Schmidt M, Rabes H, Lohrs U: DNA ploidy and MYC DNA amplification in ovarian carcinomas: correlation with p53 and bcl-2 expression, proliferative activity and prognosis. Virchows Arch 1996, 429:221-227
38. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G, Biagini G: Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995, 56:169-174
39. Barbieri F, Cagnoli M, Ragni N, Pedulla F, Foglia G, Alama A: Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 1997, 75:1263-1268
40. Bartkova L, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775-777